Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068) | Clinical Trial Compass
SuspendedNot Applicable
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
Stopped: Accrual Limit
United States5,200 participantsStarted 2017-04-18
Plain-language summary
This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.
Who can participate
Age range30 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 30 or older. Note: Participants must meet each of Criteria 1-4.
* Have access to a healthcare provider and be willing to share genetic results with that provider
* Have at least one ovary
* Have a valid United States mailing address for receipt of saliva kit
* Participants must meet any one of the following 6 criteria:
* Diagnosed with breast cancer at age 45 or younger
* Diagnosed with triple negative (negative for estrogen receptor, progesterone receptor and not human epidermal growth factor receptor 2 \[Her2\] amplified) breast cancer at 60 or younger
* Have one blood relative with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, or PMS2
* Have one relative with ovarian cancer
* Have at least 2 relatives with breast cancer on the same side of the family, one of which is =\< 50 years of age
* Have one male relative with breast cancer
Exclusion Criteria:
* Personal history of ovarian cancer
* Unable to read, speak, and understand English
* Unable to provide informed consent
* Unwilling to complete baseline and follow-up questionnaires
* Unable to access the internet
* Previous genetic testing or counseling regarding cancer risk
* Previous bone marrow transplant
* Previous blood transfusion (7 days prior to genetic testing)
* Active hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)